CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cull

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progre

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progre

I think Cullinan Therapeutics' recent pullback is a compelling price entry ahead of their clinical u

Cullinan Therapeutics NASDAQ: CGEM outlined upcoming clinical milestones across its immunology and o

HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and mainta

Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November  CLN-978 (

CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cul

Engineers Gate Manager LP raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ: CGEM) b

BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises

Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a c

Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM)

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceuti

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemo

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemo

Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value d

Bank of America Corp DE lifted its stake in Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 49.2% in t

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial,

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial,

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with

Taiho Oncology Inc., Taiho Pharmaceutical Co. Ltd., and Cullinan Therapeutics Inc. (NASDAQ:CGEM) on

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating a

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform a

Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interi

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.81) per share which beat the an

CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion st

BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises

Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a clinical-stage biopharmaceutical

CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cull

Cullinan Therapeutics remains a compelling buy as zipalertinib approaches a key FDA decision for EGF

Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and

New and updated clinical data to be presented from over 30 patients across systemic lupus erythemato

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating p

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and mainta

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating p

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform a

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.75) per share which beat the an

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and mainta

HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a

https://www.sec.gov/Archives/edgar/data/1789972/000119312526183596/d587157ds3asr.htm